H.C. Wainwright Maintains Ionis Rating on Zanvastro Approval

Analysts at H.C. Wainwright have reaffirmed their rating on Ionis Pharmaceuticals, pointing to the recent regulatory approval of Zanvastro as a key catalyst for future growth.